Artículos de revistas
Systematic Review And Meta-analysis Of Target Terapies For The Treatment Of Metastatic Renal Cancer
Registro en:
International Braz J Urol. , v. 39, n. 6, p. 768 - 778, 2013.
16775538
10.1590/S1677-5538.IBJU.2013.06.02
2-s2.0-84894103753
Autor
Duran M.
Matheus W.
Ferreira U.
Clark O.
Institución
Resumen
Objectives: At present there are several drugs for the treatment of advanced renal cell carcinoma (ARCC). The main objective of this work was to perform a systematic review (SR) and meta-analysis (MA) of clinical randomized studies that compared target cell therapies (TCT). Materials and Methods: SR identified clinical randomized trials that compared TCT versus interferon-alpha in the treatment of patients with ARCC. In order to analyze efficiency, it was evaluated free-survival progression (FSP), total survival (TS) and response rate (RR). Results: In relation to first line treatment, seven studies of TCT were identified using sunitinib, sorafenib, bevacizumab and temsirolimus; and two studies with sorafenib and everolimus for second line treatment. Relative risk (RRi) of MA for FSP of first line therapies was: 0.83, CI = 0.78-0.87, I2 = 94% and p < 0.00001. Best results of RR of specific FSP among studies were: 0.38, sunitinib, CI = 0.25-0.58, bevacizumab, 0.62, CI = 0.47-0.83; and temsirolimus, 0.78, CI = 0.70-0.87. MA didn't show any benefit regarding TS of first line treatment of all analyzed drugs. As for RR significant results were: sunitinib, 3.83 CI = 2.86-5.12; bevacizumab, 2.52 CI = 1.78-3.57 and bevacizumab, 1.97 CI = 1.43-2.71. Conclusions: For first line treatment, sunitinib was the most effective TCT in relation to FPS; there was no alteration of TS and RR was small but significant for sunitinib and bevacizumab. Available studies could not conclude any results for second line treatments. 39 6 768 778 Fisher, R.I., Rosenberg, S.A., Fyfe, G., Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma (2000) Cancer J Sci Am, 6 (SUPPL. 1), pp. S55-S57 McDermott, D.F., Regan, M.M., Clark, J.I., Flaherty, L.E., Weiss, G.R., Logan, T.F., Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients withmetastatic renal cell carcinoma (2005) J Clin Oncol, 23, pp. 133-141. , Erratum in: J Clin Oncol. 2005 23: 2877 Motzer, R.J., Murphy, B.A., Bacik, J., Schwartz, L.H., Nanus, D.M., Mariani, T., Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma (2000) J Clin Oncol, 18, pp. 2972-2980 Yang, J.C., Sherry, R.M., Steinberg, S.M., Topalian, S.L., Schwartzentruber, D.J., Hwu, P., Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer (2003) J Clin Oncol, 21, pp. 3127-3132 Higgins, J.P.T., Green, S., (2008) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2, , http://www.cochrane-handbook.org, [updated September 2009]: The Cochrane Collaboration (2008), http://ims.cochrane.org/home, The Nordic Cochrane Centre. Review Manager (RevMan) [Computer program]. Version 5.0. Copenhagen: The Cochrane CollaborationHiggins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses (2003) BMJ, 327, pp. 557-560 Cella, D., Li, J.Z., Cappelleri, J.C., Bushmakin, A., Charbonneau, C., Kim, S.T., Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial (2008) J Clin Oncol, 26, pp. 3763-3769 Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial (2007) Lancet, 370, pp. 2103-2111 Escudier, B., Szczylik, C., Hutson, T.E., Demkow, T., Staehler, M., Rolland, F., Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma (2009) J Clin Oncol, 27, pp. 1280-1289. , Erratum in: J Clin Oncol. 2009 27: 2305 Escudier, B., Bellmunt, J., Négrier, S., Bajetta, E., Melichar, B., Bracarda, S., Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysisof overall survival (2010) J Clin Oncol, 28, pp. 2144-2150 Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma (2007) N Engl J Med, 356, pp. 2271-2281 Motzer, R.J., Hutson, T.E., Tomczak, P., Michaelson, M.D., Bukowski, R.M., Rixe, O., Sunitinib versus interferon alfa in metastatic renal-cell carcinoma (2007) N Engl J Med, 356, pp. 115-124 Motzer, R.J., Hutson, T.E., Tomczak, P., Michaelson, M.D., Bukowski, R.M., Oudard, S., Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cellcarcinoma (2009) J Clin Oncol, 27, pp. 3584-3590 Rini, B.I., Halabi, S., Rosenberg, J.E., Stadler, W.M., Vaena, D.A., Ou, S.S., Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 (2008) J Clin Oncol, 26, pp. 5422-5428 Rini, B.I., Halabi, S., Rosenberg, J.E., Stadler, W.M., Vaena, D.A., Archer, L., Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cellcarcinoma: final results of CALGB 90206 (2010) J Clin Oncol, 28, pp. 2137-2143 Yang, S., de Souza, P., Alemao, E., Purvis, J., Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha (2010) Br J Cancer, 102, pp. 1456-1460 Escudier, B., Eisen, T., Stadler, W.M., Szczylik, C., Oudard, S., Siebels, M., Sorafenib in advanced clear-cell renal-cell carcinoma (2007) N Engl J Med, 356, pp. 125-134. , Erratum in: N Engl J Med. 2007 357: 203 Motzer, R.J., Escudier, B., Oudard, S., Hutson, T.E., Porta, C., Bracarda, S., Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial (2008) Lancet, 372, pp. 449-456 Bukowski, R., Cella, D., Gondek, K., Escudier, B., Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renalcancer (2007) Am J Clin Oncol, 30, pp. 220-227. , Sorafenib TARGETs Clinical Trial Group Sternberg, C.N., Davis, I.D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial (2010) J Clin Oncol, 28, pp. 1061-1068 Rexer, H., First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell cancer (SWITCH-2-AN 33/11)] (2012) Urologe A, 51, pp. 724-726 Rini, B.I., Escudier, B., Tomczak, P., Kaprin, A., Szczylik, C., Hutson, T.E., Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial (2011) Lancet, 378, pp. 1931-1939. , Erratum in: Lancet. 2012 380: 1818 Nosov, D.A., Esteves, B., Lipatov, O.N., Lyulko, A.A., Anischenko, A.A., Chacko, R.T., Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cellcarcinoma (2012) J Clin Oncol, 30, pp. 1678-1685